Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naïve non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel.
Mohamad Abou ChakraRiitta LassilaNancy El BeayniSarah L MottMichael A O'DonnellPublished in: BJU international (2024)
Pre-treatment NLR provides some predictive accuracy for RFS in high-risk BCG-naïve patients receiving Gem/Doce. Further prospective trials are needed to validate this finding.